Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295280963> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W4295280963 endingPage "S172" @default.
- W4295280963 startingPage "S171" @default.
- W4295280963 abstract "The RENOWNED study investigated the treatment patterns, real-world effectiveness and safety of ranibizumab in Taiwanese patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab 0.5 mg in accordance with the first reimbursement scheme effective from 2012 to 2014.This study was a Phase IV, 12-month, open-label, prospective, observational study conducted in Taiwan. Patients with visual impairment due to nAMD initiating treatment with ranibizumab 0.5 mg were included. The primary endpoint was mean change in best-corrected visual acuity (BCVA) from Baseline at Month 3.Overall, 202 patients with nAMD were included. Mean (standard deviation [SD]) BCVA Early Treatment Diabetic Retinopathy Study letters improved from Baseline (49.6 [21.5] letters) at Month 3 (+4.9 [11.8], P < 0.0001), and at Month 12 (+3.5 [14.1], P = 0.0043). The proportion of patients with nAMD who lost ≥5 letters at Months 3 and 12 was 13.6% (n = 27) and 26.6% (n = 37), respectively. Mean (SD) central retinal thickness decreased from Baseline (320.1 [127.2] μm) with a mean reduction of 49.1 (107.3) μm at Month 3 (P < 0.0001), but was not significant at Month 12 with a mean reduction of 11.6 (115.6) μm (P = 0.2861). Mean (SD) number of ranibizumab injections over 12 months was 3.1 (1.0). A mean treatment interval of 109.5 days was observed between the third and fourth injections. After limited reimbursed ranibizumab injections, 43.8% patients received other treatments. The safety findings are consistent with previous studies.Ranibizumab 0.5 mg treatment for 12 months under real-world settings improved visual outcomes in Taiwanese patients with nAMD." @default.
- W4295280963 created "2022-09-12" @default.
- W4295280963 creator A5032623023 @default.
- W4295280963 creator A5077840950 @default.
- W4295280963 date "2022-09-01" @default.
- W4295280963 modified "2023-09-25" @default.
- W4295280963 title "P11-23 Investigating the ability of HepaRG cells to recapitulate antibioticinduced mitochondrial dysfunction in order to elucidate hepatotoxicity mechanisms" @default.
- W4295280963 doi "https://doi.org/10.1016/j.toxlet.2022.07.473" @default.
- W4295280963 hasPublicationYear "2022" @default.
- W4295280963 type Work @default.
- W4295280963 citedByCount "0" @default.
- W4295280963 crossrefType "journal-article" @default.
- W4295280963 hasAuthorship W4295280963A5032623023 @default.
- W4295280963 hasAuthorship W4295280963A5077840950 @default.
- W4295280963 hasConcept C118487528 @default.
- W4295280963 hasConcept C126322002 @default.
- W4295280963 hasConcept C134018914 @default.
- W4295280963 hasConcept C203092338 @default.
- W4295280963 hasConcept C2776403814 @default.
- W4295280963 hasConcept C2776694085 @default.
- W4295280963 hasConcept C2777802072 @default.
- W4295280963 hasConcept C2778257484 @default.
- W4295280963 hasConcept C2779829184 @default.
- W4295280963 hasConcept C2780827179 @default.
- W4295280963 hasConcept C2781100027 @default.
- W4295280963 hasConcept C535046627 @default.
- W4295280963 hasConcept C555293320 @default.
- W4295280963 hasConcept C71924100 @default.
- W4295280963 hasConceptScore W4295280963C118487528 @default.
- W4295280963 hasConceptScore W4295280963C126322002 @default.
- W4295280963 hasConceptScore W4295280963C134018914 @default.
- W4295280963 hasConceptScore W4295280963C203092338 @default.
- W4295280963 hasConceptScore W4295280963C2776403814 @default.
- W4295280963 hasConceptScore W4295280963C2776694085 @default.
- W4295280963 hasConceptScore W4295280963C2777802072 @default.
- W4295280963 hasConceptScore W4295280963C2778257484 @default.
- W4295280963 hasConceptScore W4295280963C2779829184 @default.
- W4295280963 hasConceptScore W4295280963C2780827179 @default.
- W4295280963 hasConceptScore W4295280963C2781100027 @default.
- W4295280963 hasConceptScore W4295280963C535046627 @default.
- W4295280963 hasConceptScore W4295280963C555293320 @default.
- W4295280963 hasConceptScore W4295280963C71924100 @default.
- W4295280963 hasLocation W42952809631 @default.
- W4295280963 hasOpenAccess W4295280963 @default.
- W4295280963 hasPrimaryLocation W42952809631 @default.
- W4295280963 hasRelatedWork W1751609384 @default.
- W4295280963 hasRelatedWork W1964041030 @default.
- W4295280963 hasRelatedWork W2080677442 @default.
- W4295280963 hasRelatedWork W2093126039 @default.
- W4295280963 hasRelatedWork W2139018208 @default.
- W4295280963 hasRelatedWork W2143479083 @default.
- W4295280963 hasRelatedWork W2281889375 @default.
- W4295280963 hasRelatedWork W3029764562 @default.
- W4295280963 hasRelatedWork W4210792680 @default.
- W4295280963 hasRelatedWork W2343548146 @default.
- W4295280963 hasVolume "368" @default.
- W4295280963 isParatext "false" @default.
- W4295280963 isRetracted "false" @default.
- W4295280963 workType "article" @default.